CommentaryEndoxifen Approval for Bipolar Disorder in India A Premature or a Pragmatic Decision?Gupta, Rishab MD1; Singh, Swarndeep MD2 Author Information From the 1Behavioral Neurology & Neuropsychiatry Fellow, Department of Psychiatry, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 2Assistant Professor, Government Medical College and Hospital, Chandigarh, India. Received May 17, 2022; accepted after revision September 17, 2022. Address correspondence to: Rishab Gupta, MD, Department of Psychiatry, 1153 Centre Street, Boston, MA, 02130. E-mail: ([email protected]; [email protected]). The authors declare no conflicts of interest. A podcast discussing this article is available online at the journal website. Journal of Clinical Psychopharmacology 43(1):p 3-5, 1/2 2023. | DOI: 10.1097/JCP.0000000000001643 Buy Metrics Abstract In this commentary, we critique the Indian government's decision to approve endoxifen for the treatment of acute mania among adults. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.